APA

Blesius A., Beuselinck B., Chevreau C., Ravaud A., Rolland F., Oudard S. & Escudier B. (20140213). Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. : Clinical genitourinary cancer.

Chicago

Blesius Aurore, Beuselinck Benoit, Chevreau Christine, Ravaud Alain, Rolland Frédéric, Oudard Stéphane and Escudier Bernard. 20140213. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. : Clinical genitourinary cancer.

Harvard

Blesius A., Beuselinck B., Chevreau C., Ravaud A., Rolland F., Oudard S. and Escudier B. (20140213). Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. : Clinical genitourinary cancer.

MLA

Blesius Aurore, Beuselinck Benoit, Chevreau Christine, Ravaud Alain, Rolland Frédéric, Oudard Stéphane and Escudier Bernard. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. : Clinical genitourinary cancer. 20140213.